Propanc to investigate "mesenchymal drift" for chronic disease reversal.

Propanc Biopharma plans to investigate "mesenchymal drift," a concept that may unlock mechanisms for reversing chronic diseases. This area of research aligns with the company's expanding research efforts into how its lead product candidate, PRP, influences the epithelial-to-mesenchymal transition (EMT) and related pathways. Propanc has filed a patent application describing a PRP-based treatment method for fibrotic disease.